Genetic Markers of Response to Newer Therapies for Type 2 Diabetes

Not Applicable

• Conditions: E11; Type 2 diabetes mellitus

• Registration Number: DRKS00034478
• Lead Sponsor: Faculty of Medicine, University of Ljubljana

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-07-25
• Study Start: 2024-06-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 161

Inclusion Criteria

Criteria 1: previous diagnosis of type 2 diabetes mellitus
Criteria 2: met the inclusion criteria for treatment with newer antihyperglycaemic drugs (SGLT2 inhibitors and/or GLP-1RA inhibitors)

Exclusion Criteria

Criteria 1: other types of diabetes mellitus
Criteria 2: patients with significant cognitive impairment or psychiatric disorder
Criteria 3: patients abusing alcohol or other drugs
Criteria 4: patients with cancer or a history of cancer in the last 5 years)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glycated haemoglobin (HbA1c), body weight, and blood pressure, before starting treatment with SGLT2 and/or GLP-1RA and after 3-6 months of treatment.

Secondary Outcome Measures

Name	Time	Method
Genotype distribution for two GLP1R polymorphisms (rs6923761 and rs10305420) and one SLC5A2 polymorphism (rs9934336), using competitive allele-specific polymerase chain reaction (KASP)